Cambridge Investment Research Advisors’s Elevance Health ELV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $12M | Buy |
30,940
+2,922
| +10% | +$1.08M | 0.03% | 591 |
|
|
2026
Q1 | $8.2M | Buy |
28,018
+266
| +1% | +$87.4K | 0.02% | 700 |
|
|
2025
Q4 | $9.73M | Buy |
27,752
+634
| +2% | +$214K | 0.03% | 595 |
|
|
2025
Q3 | $8.76M | Sell |
27,118
-1,850
| -6% | -$575K | 0.02% | 629 |
|
|
2025
Q2 | $11.3M | Sell |
28,968
-4,336
| -13% | -$1.74M | 0.03% | 499 |
|
|
2025
Q1 | $14.5M | Buy |
33,304
+2,901
| +10% | +$1.16M | 0.05% | 384 |
|
|
2024
Q4 | $11.2M | Sell |
30,403
-848
| -3% | -$355K | 0.04% | 447 |
|
|
2024
Q3 | $16.3M | Sell |
31,251
-1,216
| -4% | -$650K | 0.06% | 339 |
|
|
2024
Q2 | $17.6M | Buy |
32,467
+4,566
| +16% | +$2.41M | 0.07% | 291 |
|
|
2024
Q1 | $14.5M | Buy |
27,901
+4,271
| +18% | +$2.12M | 0.06% | 339 |
|
|
2023
Q4 | $11.1M | Sell |
23,630
-798
| -3% | -$369K | 0.05% | 369 |
|
|
2023
Q3 | $10.6M | Buy |
24,428
+2,270
| +10% | +$1.03M | 0.05% | 365 |
|
|
2023
Q2 | $9.85M | Buy |
22,158
+6,216
| +39% | +$2.87M | 0.04% | 393 |
|
|
2023
Q1 | $7.33M | Sell |
15,942
-2,169
| -12% | -$1.03M | 0.04% | 463 |
|
|
2022
Q4 | $9.29M | Sell |
18,111
-1,749
| -9% | -$888K | 0.05% | 388 |
|
|
2022
Q3 | $9.02M | Buy |
19,860
+824
| +4% | +$394K | 0.05% | 349 |
|
|
2022
Q2 | $9.19M | Sell |
19,036
-240
| -1% | -$119K | 0.05% | 357 |
|
|
2022
Q1 | $9.47M | Buy |
19,276
+269
| +1% | +$123K | 0.04% | 392 |
|
|
2021
Q4 | $8.81M | Buy |
19,007
+1,524
| +9% | +$641K | 0.04% | 421 |
|
|
2021
Q3 | $6.52M | Sell |
17,483
-1,367
| -7% | -$520K | 0.03% | 502 |
|
|
2021
Q2 | $7.2M | Buy |
18,850
+913
| +5% | +$349K | 0.03% | 484 |
|
|
2021
Q1 | $6.44M | Sell |
17,937
-710
| -4% | -$228K | 0.04% | 481 |
|
|
2020
Q4 | $5.99M | Sell |
18,647
-6,123
| -25% | -$1.88M | 0.04% | 459 |
|
|
2020
Q3 | $6.65M | Buy |
24,770
+3,369
| +16% | +$906K | 0.04% | 377 |
|
|
2020
Q2 | $5.63M | Buy |
21,401
+751
| +4% | +$200K | 0.04% | 399 |
|
|
2020
Q1 | $4.69M | Sell |
20,650
-14,763
| -42% | -$4.02M | 0.05% | 380 |
|
|
2019
Q4 | $10.7M | Buy |
35,413
+4,360
| +14% | +$1.2M | 0.08% | 237 |
|
|
2019
Q3 | $7.46M | Buy |
31,053
+1,679
| +6% | +$460K | 0.07% | 291 |
|
|
2019
Q2 | $8.29M | Buy |
29,374
+4,258
| +17% | +$1.16M | 0.08% | 254 |
|
|
2019
Q1 | $7.21M | Buy |
25,116
+14,819
| +144% | +$4.29M | 0.07% | 267 |
|
|
2018
Q4 | $2.7M | Sell |
10,297
-99
| -1% | -$27.2K | 0.03% | 542 |
|
|
2018
Q3 | $2.85M | Sell |
10,396
-1,034
| -9% | -$268K | 0.03% | 563 |
|
|
2018
Q2 | $2.72M | Sell |
11,430
-670
| -6% | -$155K | 0.03% | 540 |
|
|
2018
Q1 | $2.66M | Sell |
12,100
-15,333
| -56% | -$3.6M | 0.03% | 536 |
|
|
2017
Q4 | $6.17M | Buy |
27,433
+95
| +0.3% | +$20.2K | 0.07% | 262 |
|
|
2017
Q3 | $5.19M | Buy |
27,338
+418
| +2% | +$79.6K | 0.07% | 272 |
|
|
2017
Q2 | $5.07M | Buy |
+26,920
| New | +$4.84M | 0.07% | 251 |
|
|
2016
Q4 | – | Sell |
-19,308
| Closed | -$2.42M | – | 1747 |
|
|
2016
Q3 | $2.42M | Buy |
+19,308
| New | +$2.49M | 0.04% | 378 |
|
|
2016
Q2 | – | Sell |
-12,192
| Closed | -$1.7M | – | 1623 |
|
|
2016
Q1 | $1.7M | Buy |
12,192
+1,001
| +9% | +$134K | 0.04% | 401 |
|
|
2015
Q4 | $1.56M | Buy |
+11,191
| New | +$1.54M | 0.04% | 421 |
|
|
2014
Q4 | – | Sell |
-6,471
| Closed | -$774K | – | 1394 |
|
|
2014
Q3 | $774K | Buy |
6,471
+843
| +15% | +$96.7K | 0.02% | 611 |
|
|
2014
Q2 | $606K | Buy |
5,628
+447
| +9% | +$46.1K | 0.02% | 659 |
|
|
2014
Q1 | $516K | Sell |
5,181
-72
| -1% | -$6.51K | 0.02% | 706 |
|
|
2013
Q4 | $485K | Buy |
5,253
+735
| +16% | +$65.3K | 0.02% | 668 |
|
|
2013
Q3 | $378K | Buy |
4,518
+5
| +0.1% | +$429 | 0.02% | 737 |
|
|
2013
Q2 | $369K | Buy |
+4,513
| New | +$338K | 0.02% | 673 |
|
Other funds holding ELV
Cambridge Investment Research Advisors's ELV Position: Q2 2026 in Review
Cambridge Investment Research Advisors increased its Elevance Health (ELV) stake by 10% in Q2 2026, buying an estimated $1.08M and bringing the position to 30,940 shares worth $12M. The position accounts for 0.03% of the portfolio, ranked #591.
Cambridge Investment Research Advisors first reported a position in ELV in Q2 2013 and has held it in 46 quarters since. The position peaked at $17.6M in Q2 2024. 1,601 funds tracked by Wall St. Rank hold ELV as of Q2 2026.
- Cambridge Investment Research Advisors held 30,940 shares of Elevance Health worth $12M as of Q2 2026.
- Cambridge Investment Research Advisors bought 2,922 Elevance Health shares in Q2 2026, an estimated $1.08M.
- Elevance Health made up 0.03% of Cambridge Investment Research Advisors's portfolio in Q2 2026, its #591 holding.
- Cambridge Investment Research Advisors first reported a position in Elevance Health in Q2 2013 and has held it in 46 quarters since.
- Cambridge Investment Research Advisors's Elevance Health position peaked at $17.6M in Q2 2024.
- 1,601 funds tracked by Wall St. Rank held Elevance Health as of Q2 2026.
Based on Cambridge Investment Research Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.